VitaNova Life Sciences EBITDA Growth & History (VNOV)
VitaNova Life Sciences's calculated EBITDA was $6,581 for fiscal 2026.
View full VitaNova Life Sciences company overviewVitaNova Life Sciences annual ebitda history
2018
2019
2023
2024
2025
2026
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-04-30 | $6,581 | −$1.2M | −99.46% |
| 2025 | 2025-04-30 | $1.2M | $1.0M | +487.56% |
| 2024 | 2024-04-30 | $205,734 | $229,961 | — |
| 2023 | 2023-04-30 | −$24,227 | — | — |
| 2019 | 2019-04-30 | −$71,811 | −$23,162 | — |
| 2018 | 2018-04-30 | −$48,649 | — | — |
VitaNova Life Sciences quarterly ebitda
Q3.18
Q3.18
Q1.19
Q3.19
Q1.20
Q4.25
Q1.26
Q2.26
Q3.26
Q4.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q4 2026 | 2026-04-30 | −$107,000 | −$1.2M | — |
| Q3 2026 | 2026-01-31 | $46,731 | — | — |
| Q2 2026 | 2025-10-31 | $99,290 | — | — |
| Q1 2026 | 2025-07-31 | −$32,440 | — | — |
| Q4 2025 | 2025-04-30 | $1.1M | — | — |
| Q1 2020 | 2019-07-31 | −$19,884 | −$6,425 | — |
| Q3 2019 | 2019-01-31 | −$36,696 | −$36,696 | — |
| Q1 2019 | 2018-07-31 | −$13,459 | — | — |
| Q3 2018 · Jan 31 | 2018-01-31 | $0 | — | — |
| Q3 2018 · Oct 31 | 2017-10-31 | $7,278 | — | — |
VitaNova Life Sciences ebitda trends
Between the periods ended 2018-04-30 and 2026-04-30, VitaNova Life Sciences's ebitda increased from −$48,649 to $6,581, a change of $55,230. The latest reported quarter, Q4 2026, shows −$107,000.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review VitaNova Life Sciences source filings ↗